Optimizing the management of her2-positive early breast cancer: The clinical reality

Current Oncology

Volumn 17, Issue 4, 2010, Pages 20-33

  Verma, Su ^a   Lavasani, S ^b   Mackey, J ^c   Pritchard, K ^d   Clemons, M ^e   Dent, S ^f   Latreille, J ^g   Lemieux, J ^g   Provencher, L ^h   Verma, Sh ⁱ   Chia, S ^j   Wang, B ^a   Rayson, D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITÉ DE SHERBROOKE   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ Remedy Communications Limited   (Canada)

^j QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

Adjuvant; Early breast cancer; Her2 positive; Node negative; Trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION; TUMOR VOLUME;

EID: 78149472680     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i4.700     Document Type: Article

References (43)

1. Canadian Cancer Society. Home > About Cancer > Cancer Statistics > Statistics at a Glance > Breast Cancer Statistics [Web page]. Toronto, ON: Canadian Cancer Society; 2010. [Available online at: www.cancer.ca/Ontario/About%20cancer/Cancer%20statistics/Stats%20at%20a% 20glance/Breast%20cancer.aspx?sc_lang=en&r=1; cited May 31, 2010].
2. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumour action. Cancer Res 2002;62:4132-41.
3. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-38.
4. Longva KE, Pedersen NM, Hasleka˚s C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116:359-67.
5. Migliaccio I, Gutierrez MC, Wu MF, et al. pi3 kinase activation and response to trastuzumab or lapatinib in her-2 overexpressing locally advanced breast cancer (labc) [abstract 34]. San Antonio, TX: San Antonio Breast Cancer Symposium; 2008. [Available online at: www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_1226&terms=; cited May 11, 2010].
6. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49.
7. Izumi Y, Xu L, Di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80.
8. Wen XF, Yang G, Mao W, et al. her2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for her2-targeted antibody therapy. Oncogene 2006;25:6986-96.
9. Klos KS, Zhou X, Lee S, et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98:1377-85.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
11. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing her2. Clin Cancer Res 2004;10:5650-5.
12. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of her2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67.
13. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-her2 receptor monoclonal antibody, inhibits basal and activated her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
14. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
15. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer V.2.2010. Fort Washington, PA: nccn; 2010. [Available online at: www.nccn.org/professionals/physician_gls/PDF/breast.pdf (free registration required); cited May 31, 2010].
16. Dent S, Verma S, Latreille J, et al. The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer. Curr Oncol 2009;16:25-35.
17. Lemieux J, Clemons M, Provencher L, et al. The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers. Curr Oncol 2009;16:48-57.
18. Gianni L, Goldhirsch A, Gelber RD, et al. on behalf of the hera study team. Update of the hera trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer [abstract S25]. Breast 2009;18(suppl 1);S11. [Available online at: ex2.excerptamedica.com/ciw-09ptebc/index.cfm?fuseaction=CIS2002&hoofdnav =Abstracts&content=abs.details&what=AUTHOR&searchtext=Gianni&topicselect ed=*&selection=ABSTRACT&qryStartRowDetail=1; cited May 11, 2010].
19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N Engl J Med 2005;353:1673-84.
20. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of ncctg N9831 and nsabp B-31 adjuvant chemotherapy with/without trastuzumab in patients with her2-positive breast cancer [abstract 512]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=4 7&abstractID=35229; cited May 11, 2010 (followed the link under "Associated Presentation(s)" for the conference video with E. Perez)].
21. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of52 weeks of trastuzumab in the ncctg N9831 her2-positive adjuvant breast cancer trial [abstract 80]. San Antonio, TX: San Antonio Breast Cancer Symposium; 2009. [Available online at: www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_992332&terms=; cited May 11, 2010].
22. Slamon D, Eiermann W, Robert N, et al. Phase iii randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ac→t) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ac→th) with docetaxel, carboplatin and trastuzumab (tch) in her2neu positive early breast cancer patients: bcirg 006 study [abstract 62]. San Antonio, TX: San Antonio Breast Cancer Symposium; 2009. [Available online at: www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1752; cited May 11, 2010].
23. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the finher Trial. J Clin Oncol 2009;27:5685-92.
24. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the fnclcc-pacs 04 trial. J Clin Oncol 2009;27:6129-34.
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med 2005;353:1659-72.
26. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in her2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
27. Slamon D, Eiermann W, Robert N, et al. bcirg 006: 2nd interim analysis phase iii randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ac→t) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ac→th) with docetaxel, carboplatin and trastuzumab (tch) in her2neu positive early breast cancer patients [abstract 52]. San Antonio, TX: San Antonio Breast Cancer Symposium; 2006. [Available online at: www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_78&terms=; cited June 14, 2010].
28. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
29. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on nsabp B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (ac) → paclitaxel (t) vs. ac → t with trastuzumab (h) [abstract LBA513]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&conf ID=47&abstractID=33932; cited April 27, 2010 (follow the link under "Associated Presentation(s)" for the conference video with P. Rastogi)].
30. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-8.
31. Au HJ, Robert N, Eiermann W, et al. bcirg 006: Quality of life (qol) of patients (pts) treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative her2 positive early breast cancer [abstract 3064]. Breast Cancer Res Treat 2007;106(suppl 1):. [Available online at: www.abstracts2view.com/sabcs07/view.php?nu=SABCS07L_281&terms=; cited May 11, 2010].
32. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26:5697-704.
33. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700-6.
34. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of her2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693-9.
35. Black D, Younger J, Martei Y, et al. Recurrence risk in T1a-b, node negative, her2 positive breast cancer [abstract 2037]. Breast Cancer Res Treat 2006;100(suppl 1):S92.
36. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003;9:923-30.
37. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Treatment of node-negative infra-centimetric her2+ invasive breast carcinomas: a joint aerio/remagus study [abstract 517]. Proc Am Soc Clin Oncol 2009;27:15(suppl):. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=6 5&abstractID=33873; cited May 11, 2010].
38. McArthur HL, Morris PG, Patil S, et al. Benefits of trastuzumab-based therapy for women with small, node-negative, her2-positive breast cancer [abstract 228]. Proc Am Soc Clin Oncol Breast Cancer Symp 2009;:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=7 0&abstractID=40480; cited May 11, 2010].
39. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the hera trial. Ann Oncol 2008;19:1090-6.
40. Trudeau M, Madarnas Y, McCready D, Pritchard KI, Messersmith H, and the Breast Cancer Disease Site Group. The Role of Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-Overexpressing Breast Cancer: A Clinical Practice Guideline. Evidence-based series 1-24. Section 1. Toronto: Cancer Care Ontario, Program in Evidence-Based Care; 2006. [Available online at: www.cancercare.on.ca/pdf/pebc1-24s.pdf; cited April 27, 2010].
41. BC Cancer Agency (bcca). 041 Adjuvant Trastuzumab Therapy [Web page]. Vancouver, BC: bcca; 2009. [Available at: www. bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/ Management/041+Adjuvant+Trastuzumab+Therapy.htm; cited April 27, 2010].
42. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
43. Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24-35.